Typbar-TCV

BIOLOGICAL2 trials

Sponsors

EuBiologics Co.,Ltd, University of Maryland, Baltimore

Conditions

Trivalent Salmonella Conjugate Vaccine (TSCV)Typhoid Fever

Phase 2

Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants

CompletedNCT04830371

EuBiologics Co.,LtdTyphoid Fever

Start: 2020-09-07End: 2021-08-01Updated: 2021-10-07

Trivalent Salmonella Conjugate Vaccine (TSCV)

Active, not recruitingNCT05784701

University of Maryland, BaltimoreTrivalent Salmonella Conjugate Vaccine (TSCV)

Start: 2023-04-05End: 2027-12-30Target: 800Updated: 2026-06-29

Related Papers

A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV® in healthy 6 Months-45 years aged participants.

2023-02-095 citations